𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Improvement of Renal Function After Conversion to Mycophenolate Mofetil Combined With Low-Level Calcineurin Inhibitor in Liver Transplant Recipients With Chronic Renal Dysfunction

✍ Scribed by C. Ponton; L. Vizcaíno; S. Tomé; E. Otero; E. Molina; J.F. Castroagudín; A. López-Lago; E. Varo Pérez


Book ID
116936010
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
195 KB
Volume
42
Category
Article
ISSN
0041-1345

No coin nor oath required. For personal study only.


📜 SIMILAR VOLUMES


Mycophenolate mofetil in combination wit
✍ Georges-Philippe Pageaux; Lionel Rostaing; Yvon Calmus; Christophe Duvoux; Clair 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 92 KB 👁 1 views

The purpose of the study was to introduce mycophenolate mofetil (MMF) in liver transplant recipients with renal dysfunction to decrease calcineurin inhibitor (CNI) dosages without increasing rejection risk. In this prospective, multicenter, randomized study, chronic CNI-related renal dysfunction was

Improvement of renal function after the
✍ Javier F. Castroagudín; Esther Molina; Rafael Romero; Esteban Otero; Santiago To 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 141 KB 👁 1 views

Chronic renal dysfunction is a frequent and severe complication in solid-organ transplant recipients. Calcineurin inhibitors (CNIs) are the main pathogenic factors of renal dysfunction. Switching from CNIs to nonnephrotoxic drugs, such as mammalian target of rapamycin inhibitors (everolimus and siro

Long-term effects of calcineurin inhibit
✍ Caroline Créput; Frederique Blandin; Benjamin Deroure; Bruno Roche; Faouzi Salib 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 123 KB 👁 1 views

Calcineurin inhibitors (CNIs) are the cornerstone of immunosuppression after liver transplantation. However, CNI treatment is frequently associated with chronic renal failure (CRF). The reduction or interruption of CNI may reduce renal failure. We prospectively studied 49 liver recipients treated wi